Tags

Type your tag names separated by a space and hit enter

Meloxicam reduces lipopolysaccharide-induced degeneration of dopaminergic neurons in the rat substantia nigra pars compacta.
Neurosci Lett. 2009 Aug 28; 460(2):121-5.NL

Abstract

Inflammation is believed to play an important role in the etiology and pathogenesis of Parkinson's disease (PD). However, experimental and epidemiological evidences from various non-steroidal anti-inflammatory drugs, including cyclooxygenase-2 (COX-2) inhibitors, seem contradictive. Using the intranigral lipopolysaccharide (LPS) rat model, we show that meloxicam, a preferential COX-2 inhibitor, diminishes the activation of OX-42-immunoreactive (ir) microglia and reduces the loss of tyrosine hydroxylase (TH)-ir dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) that is normally induced by exposure to LPS. Double-labelling immunohistochemistry identified that activated microglia rather than intact resting microglia are the main intracellular venues for COX-2 expression. These findings suggest that inhibition of COX-2 activity in activated microglial cells may be potentially neuroprotective for DA neurons in the SNpc.

Authors+Show Affiliations

Florey Neuroscience Institutes, The University of Melbourne, Parkville, Victoria 3010, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19450656

Citation

Sui, Yi, et al. "Meloxicam Reduces Lipopolysaccharide-induced Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra Pars Compacta." Neuroscience Letters, vol. 460, no. 2, 2009, pp. 121-5.
Sui Y, Stanić D, Tomas D, et al. Meloxicam reduces lipopolysaccharide-induced degeneration of dopaminergic neurons in the rat substantia nigra pars compacta. Neurosci Lett. 2009;460(2):121-5.
Sui, Y., Stanić, D., Tomas, D., Jarrott, B., & Horne, M. K. (2009). Meloxicam reduces lipopolysaccharide-induced degeneration of dopaminergic neurons in the rat substantia nigra pars compacta. Neuroscience Letters, 460(2), 121-5. https://doi.org/10.1016/j.neulet.2009.05.033
Sui Y, et al. Meloxicam Reduces Lipopolysaccharide-induced Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra Pars Compacta. Neurosci Lett. 2009 Aug 28;460(2):121-5. PubMed PMID: 19450656.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Meloxicam reduces lipopolysaccharide-induced degeneration of dopaminergic neurons in the rat substantia nigra pars compacta. AU - Sui,Yi, AU - Stanić,Davor, AU - Tomas,Doris, AU - Jarrott,Bevyn, AU - Horne,Malcolm K, Y1 - 2009/05/18/ PY - 2009/03/10/received PY - 2009/05/01/revised PY - 2009/05/12/accepted PY - 2009/5/20/entrez PY - 2009/5/20/pubmed PY - 2009/9/3/medline SP - 121 EP - 5 JF - Neuroscience letters JO - Neurosci Lett VL - 460 IS - 2 N2 - Inflammation is believed to play an important role in the etiology and pathogenesis of Parkinson's disease (PD). However, experimental and epidemiological evidences from various non-steroidal anti-inflammatory drugs, including cyclooxygenase-2 (COX-2) inhibitors, seem contradictive. Using the intranigral lipopolysaccharide (LPS) rat model, we show that meloxicam, a preferential COX-2 inhibitor, diminishes the activation of OX-42-immunoreactive (ir) microglia and reduces the loss of tyrosine hydroxylase (TH)-ir dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) that is normally induced by exposure to LPS. Double-labelling immunohistochemistry identified that activated microglia rather than intact resting microglia are the main intracellular venues for COX-2 expression. These findings suggest that inhibition of COX-2 activity in activated microglial cells may be potentially neuroprotective for DA neurons in the SNpc. SN - 1872-7972 UR - https://www.unboundmedicine.com/medline/citation/19450656/Meloxicam_reduces_lipopolysaccharide_induced_degeneration_of_dopaminergic_neurons_in_the_rat_substantia_nigra_pars_compacta_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304-3940(09)00657-0 DB - PRIME DP - Unbound Medicine ER -